Swiss drugmaker Roche (ROPC.S) confirmed its full-year targets on Thursday as first-half sales fell in Swiss franc terms, dragged down by a strong domestic currency.
Group sales for the first half came in at 30.36 billion Swiss francs ($37.34 billion), in line with average analyst expectations of about 30.31 billion francs cited by Visible Alpha. Roche maintained its outlook for adjusted earnings-per-share growth in a high-single-digit range and sales growth in the mid-single-digit percentage range.
Chief Executive Thomas Schinecker said the company is well positioned for growth thanks to its robust pipeline.
Analysts expect the second half of the year to be important for investor sentiment as Roche continues expanding launches of breast cancer drug Itovebi and other medicines in additional markets through the rest of 2026.
($1 = 0.8131 Swiss francs)
